| 前收市價 | 0.7000 |
| 開市 | 0.8000 |
| 買盤 | 0.7900 |
| 賣出價 | 0.9500 |
| 拍板 | 325.00 |
| 到期日 | 2024-06-21 |
| 今日波幅 | 0.7000 - 0.8800 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 1.31k |
BenzingaAmgen Secures FDA Nod For Rare-Disease Treatment Biosimilar Based On AstraZeneca's Drug
Tuesday, the FDA approved Amgen Inc (NASDAQ:AMGN) Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to AstraZeneca Plc’s (NASDAQ:AZN) Soliris (eculizumab) to treat certain rare diseases. Bkemv is approved for the following treatment indications, which are also currently approved for Soliris: The treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. The treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-medi
Motley FoolWhere Will Amgen Be in 3 Years?
The Amgen of 2027 could be much be larger than some investors expect.
ZacksBeat the Market the Zacks Way: EverQuote, Micron, Amgen in Focus
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
